Abstract: Method of forming a polymer inside the hair shaft. The polymer changes the mechanical properties of the hair, which provides styling advantages such as improved manageability. The method comprises applying an activating composition to the hair, wherein the activating composition comprises from about 0.5% to about 20% salt of thiosulfonic acid. Also related processes, uses, kits and regimens.

Abstract: This application is directed to hair and skin conditioning compositions which contain specific polyoxyalkylene substituted alkylene diamines. The polyoxyalkylene substituted alkylene diamines function as conditioning agents on hair and skin via cloud point deposition. The polyoxyalkylene substituted alkylene diamines in addition to functioning as conditioning agents on skin and hair by themselves also function to enhance deposition of lipophilic benefit agents such as for example fatty alcohols, esters of fatty acids, hydrophobic vitamin or vitamin complexes, natural or synthetic triglycerides including glyceryl esters and derivative, pearlescent waxes, hydrocarbon oils, siloxanes of silicones, perfume oils, super-fatting agents, water insoluble or slightly soluble organic sunscreens, micronized sunscreens, plant extracts, essential oils and hydrophobically modified pigments.

Abstract: The present invention relates to azomethine-type direct dyes having a triaromatic unit of formula (I) below: and also the use thereof for dyeing keratin fibres, in particular human keratin fibres such as the hair. The invention also relates to a composition for dyeing keratin fibres, comprising, in a medium suitable for dyeing, such direct dyes. Another subject of the present invention is a method for dyeing keratin fibres using said dye composition. Finally, the present invention also relates to precursors of these direct dyes.

Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

Abstract: The invention includes a neutralized amino acid ester emulsifier, emulsions and compositions containing the emulsifier, and related methods. The emulsifier is a neutralized amino acid ester that is a reaction product of a neutral amino acid with a fatty alcohol and is represented by formula (I): wherein R1 is an alkyl group that has 6 to 24 carbon atoms; R2 is an alkyl group that has 6 to 36 carbon atoms; and the amine group of the amino acid is neutralized with an acid. The emulsifier 1.0 is cationic. Also included are stable emulsions and compositions, preferably personal care compositions, that include the emulsifier and which may have pH levels of 5.5 or greater. Encompassed within the scope of the invention are methods of increasing the substantivity of a composition to a negatively charged substrate using the emulsifier, methods of emulsifying and methods of preparing a personal care composition using the emulsifier.

Abstract: The present invention relates to a method for the cosmetic treatment of keratin fibres, in particular human keratin fibres such as the hair, characterized in that it consists in applying an effective amount of a cosmetic composition comprising an aqueous dispersion of hydrophobic silica aerogel particles comprising at least one alcohol of formula (I) below, the optical isomers thereof and the solvates thereof, in particular the hydrates thereof: in which formula (I): R1 represents an —OH, —CH2OH or —CH3 group; R2 represents a hydrogenatom or an —OH group; R3 represents a hydrogen atom, a —CH2OH group, an —(O—CH2—CH2)n-OH group with n denoting an integer ranging from 1 to 10, a —(CH2—CH2)n—OH group with n denoting an integer ranging from 1 to 5 or a —CH(OH)—CH3 group, 20 the formula comprising at least one hydroxyl group.

Abstract: The present invention relates to a cosmetic composition comprising hydrophobic silica aerogel particles and one or more hydrophilic fixing polymers.

Abstract: Described herein are oral care compositions comprising (i) a whitening complex comprising crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, and (ii) a hydrogen peroxide stabilizing agent comprising a clay comprising a lithium magnesium silicate or a sodium magnesium silicate, or a combination thereof.

Abstract: A hair fixative composition includes at least one fixative polymer, a solvent system and, optionally, a propellant. The polymer is derived from at least one acid-containing monomer, at least one N-alkyl(meth)acrylamide and, optionally, an alkyl(meth)acrylate.

Abstract: The invention relates to the use of molecularly imprinted polymer(s) or MIPs, of odorous molecule(s), as deodorant agent in particular for selectively trapping molecules that are the cause of human body odour. More particularly by using MIPs which may be obtained via polymerization, preferably via radical polymerization, of a mixture of: i) optionally one or more polymerization initiator(s); ii) one or more functional monomer(s); iii) one or more crosslinking agent(s); and iv) one or more porogenic solvent(s); it being understood that the polymerization a) or b) is performed in the presence v) of one or more “templates” of target molecule(s) responsible for human body odour. Another subject of the invention concerns a process for preparing MIPs as defined previously, MIPs obtained via this process, and a cosmetic composition comprising at least one MIP as defined previously.

Abstract: This invention details a method for providing thermal protection to human hair by applying an aerosolized polymer system to the hair before heat treatment. It has been found that acrylate polymers provide good protection from the damaging affects of curling irons and straightening irons and afford improvements in the look and feel of the treated hair.

Abstract: Described herein are oral care compositions (for tooth whitening) comprising a thickening system comprising a first thickening agent and a second thickening agent, wherein the first thickening agent comprises greater than 15 wt % of the mixture of the first and second thickening agents in the thickening system. The compositions comprise crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide with a thickening system comprising silica and crosslinked polyvinylpyrrolidone.

Abstract: The invention relates to a hair care composition comprising at least one cationic film forming polymer selected from the group of Polyquaternium and at least one quaternized hyperbranched polymer having end-groups of formula (I) characterized in that said quaternized hyperbranched polymer is obtainable by preparation of a hyperbranched polymer having dimethylamino end groups by condensation of 2-dodecen-1-ylsuccinic anhydride, diisopropanolamine and N,N-bis[3-(dimethylamino)propyl]amine followed by quaternization of the dimethylamino end-groups to end groups of formula (I).

Abstract: A sunscreen composition including a polymer composition that contains a UV-absorbing polyglycerol having a UV-absorbing chromophore chemically bound thereto, and a cosmetically-acceptable topical carrier that contains at least one percent by weight of the sunscreen composition of a non-UV-absorbing polyglycerol, based on total weight of the sunscreen composition.

Abstract: A mixable multi-functional composition for application to keratin fibers such as hair, lashes or brows comprising at least one volatile solvent, at least one siloxane resin, at least one montmorillonite mineral, optionally at least one non-volatile oil, and optionally at least one wax; and a method for coloring keratin fibers comprising the steps of sequentially applying to the fibers, in any order, at least one mixable composition and at least one pigmented composition, wherein upon application the mixable composition mixes and combines with the pigmented composition in the wet state to form a final mixed composition that upon drying forms a compatible and homogeneous film.

Abstract: The present invention relates to solid compositions for making up and/or caring for the skin and/or the lips, comprising at least one fatty phase comprising: —from 5 to 30% by weight of non volatile hydrocarbonated apolar oil(s), or mixture thereof, relative to the total weight of the composition, —from 43 to 90% by weight of total content of non volatile silicone oil(s) relative to the total weight of the composition, wherein at least one of said non volatile silicone oil(s) is a non volatile phenylated silicon oil, and—from 3 to 30% by weight of wax(es), or mixture thereof, relative to the total weight of the composition.

Abstract: The present invention relates to certain novel synthetic wax powder and cosmetic composition comprising such synthetic wax powders. The present invention also relates to processes for manufacturing the wax powder having an irregular particle shape, methods of making cosmetic and personal care compositions and the use of such cosmetic compositions in topical applications.

Abstract: In one aspect, the invention relates to controlled-release devices and methods of using same, alone or in combination with other agents, to deliver pharmaceutical agents, and more particularly to deliver birth control agent, fertility agents, hormone replacement agents, cervical ripening agents, agents to prevent a sexually transmitted disease, agents to treat a sexually transmitted disease, biologics, agents to treat a mucosal infection, agents to treat uterine fibroids, agents to treat reproductive cancers, agents to treat nausea gravidarum, and/or agents to treat endometriosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Topical drugs for treating aphthae, wherein the topical drugs are in the form of a film-shaped dosage form. The topical drugs include a film made of a water-swellable or water-soluble polymer or polymer mixture, and at least one active ingredient selected from the group of tanning agents and essential oils.

Abstract: The present invention relates to effervescent tablet formulations of dapoxetine or a pharmaceutically acceptable salt thereof and a phosphodiesterase type 5 inhibitor or a pharmaceutically acceptable salt thereof. The present invention further relates to a process for preparing such a formulation and to the use thereof in the treatment of erectile dysfunction.

Abstract: Topical gel composition comprising ingenol-3-angelate and a silicone.

Abstract: Novel aqueous topical gel compositions comprising ingenol-3-angelate.

Abstract: The present invention relates to stable ready to use injectable liquid composition of chlorothiazide or its pharmaceutically acceptable salts.

Abstract: Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.

Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.

Abstract: The present invention relates to a process for the production of discrete solid extruded particles comprising dispersion droplets, to such particles as well as to the use of such particles in food, feed, pharmaceutical and personal care applications.

Abstract: A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged in an airtight package under vacuum.

Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

Abstract: The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10?4 moles to about 2.0×10?3 moles.

Abstract: The present invention relates to a pharmaceutical composition comprising a) a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, b) one or more, e.g. 1, 2 or 3, surfactants with lubricant properties; c) one or more, e.g. 1, 2 or 3, dry binders with disintegrant properties; d) one or more, e.g. 1, 2 or 3, fillers, and e) one or more, e.g. 1, 2 or 3, disintegrants.

Abstract: The invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not less than 25% of the total weight, having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm2 or more, which is obtained by granulating a powder containing an active ingredient with a binding solution containing mannitol and corn-derived pregelatinized starch, mixing the resulting granules with at least one kind of a disintegrant selected from cornstarch, hydroxypropylstarch, carmellose and crospovidone, and compression molding the mixture.

Abstract: An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.

Abstract: The invention is directed to an immediate release capsule which mitigates the abuse of Tapentadol or physiologically acceptable salt thereof by direct intravenous injection. The capsule comprises a tamper resistant formulation which when mixed with water and heated, results in a turbid, bubbling mixture that is not injectable with a standard insulin syringe.

Abstract: Addition of magnesium stearate to a powder formulation for inhalation comprising carrier particles and an active ingredient bearing a group susceptible to hydrolysis is useful for inhibiting or reducing the chemical degradation of the active ingredient.

Abstract: The application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III containing 80-95% of peripherial amines groups coated with maltotriose particles to make a drug for treating neoplastic proliferation diseases, particularly chronic lymphocytic leukemia.

Abstract: The invention provides novel methods, materials and systems that can be used to generate viral vectors having altered tissue and cell targeting abilities. In illustrative embodiments of the invention, the specificity of lentiviral vectors was modulated by a thin polymer shell that synthesized and coupled to the viral envelope in situ. The polymer shell can confers such vectors with new targeting ability via agents such as cyclic RGD (cRGD) peptides that are coupled to the polymer shell. These polymer encapsulated viral vectors exhibit a number of highly desirable characteristics including a higher thermal stability, resistance to serum inactivation in vivo, and an ability to infect dividing and non-dividing cells with high efficiencies.

Abstract: The present disclosure relates generally to a mucoadhesive nanoparticle delivery system. The nanoparticles are formed from amphiphilic macromolecules conjugated to a mucosal targeting moiety in such a manner that the surface of the nanoparticle is coated with the targeting moiety. The surface density of the targeting moiety can be tuned for adjustable targeting of the nanoparticles to a mucosal site without substantially compromising the stability of the particles. The particles were found to have high loading efficiency and sustained release properties at the mucosal site. The present disclosure also relates to polymers and macromolecules useful in the preparation of the mucoadhesive nanoparticles, as well as compositions, methods, commercial packages, kits and uses related thereto.

Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.

Abstract: The present invention relates to a combination therapy for the treatment of cancer, particularly to combinations of terpinen-4-ol and at least one additional anti-cancer therapeutic agent. The combination therapy of the present invention shows enhanced anti-cancerous therapeutic effects compared to the effect of each of the components administered alone. In some embodiments, the combination therapy provide for a synergistic anti-cancer effect.

Abstract: Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. These molecules can be delivered alone or in combination with one or more agents that inhibit bone resorption, regulate calcium resorption from bone, enhance bone accumulation, enhance bone formation, induce bone formation, impair growth of microorganisms, reduce inflammation, and/or reduce pain.

Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

Abstract: The present invention is to providing a new preparation including complex of a medical compound with lutein, astaxanthin and antioxidant. The new preparation includes stabilized liposome preparation, sustained release preparation and polymeric micelles preparation which used as delivery systems for lutein, astaxanthin and antioxidant. The new preparation significantly increases bioavailability of lutein and astaxanthin and uses for treatment and prevention of eyes and other disease.

Abstract: The invention relates to the use of effective amount of Pelargonium graveolens essential oil or extract or constituents thereof selected from a group consisting of: (S)(?)citronellol, linalool, menthone and isomenthone or any combination thereof, in the preparation of a medicament for treating a mammal suffering from or susceptible to a neurodegenerative condition which can be improved or prevented by inhibition of acetylcholinesterase (ACliE).

Abstract: The invention concerns a topical oral composition comprising taurine, propanediol and xylitol and its use for alleviating or eliminating symptoms of dry mouth and/or preventing or treating mouth ulcers.

Abstract: Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.

Abstract: The present invention relates to a pharmaceutical composition comprising, in at least one pharmaceutically acceptable support or vehicle, a combination of (3S,3S?)4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type I antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.

Abstract: Potassium ion channel opening agents, other than ATP-sensitive potassium channel opening agents, have the ability to stimulate hair growth when topically applied to the scalp.

Abstract: A compound of Formula (I), or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof wherein: m is an integer from 2 to 5 inclusive; and n is an integer from 3 to 8 inclusive; and X1 and X2 are each independently sulfur, oxygen, a sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen. Such a compound may be useful for treating, inhibiting, or preventing the progression of amyotrophic lateral sclerosis, primary lateral sclerosis, or familial amyotrophic lateral sclerosis, or a symptom of each thereof.

Abstract: Administration of a 1-phenylalkanecarboxylic acid before, after, or a concurrently with a therapeutically effective amount of one or more of the following: (1) ?-amyloid peptides level reducers, (2) pathogenic level tau reducers, (3) microtubule stabilizers, (4) agents capable or removing atherosclerotic plaques, (5) agents that lower circulating levels of ?-amyloid and tau, (6) modulators of autophagy, (7) neurotransmitter levels regulators, (8) GABA(A) ?5 Receptor Antagonists, and (9) additional agents that help maintain and/or restore cognitive function and functional deficits of AD, and/or slow down decline in cognitive functions and functional deficits in AD, is useful for prevention or therapeutical treatment of proteinopathies and/or neurodegenerative diseases.

Abstract: The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.